{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He QY"],"funding":["Jiangxi University of Traditional Chinese Medicine","National Key Research and Development Program of China"],"pagination":["643446"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8117241"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12"],"pubmed_abstract":["<b>Objectives:</b> Danhong injections (DHI) are widely used in the treatment of acute myocardial infarction (AMI). As there are no guidelines for the timing of DHI in the peri-percutaneous coronary intervention (PCI) period for AMI, we investigated the effects of DHI timing. <b>Methods:</b> We reviewed reports published before September 30, 2020 in PubMed, embase, the Cochrane Central Register of Controlled Trials, the Chinese BioMedical database, Chinese VIP database, Wanfang database, and Chinese National Knowledge Infrastructure database. Only randomized controlled trials of DHI with percutaneous coronary intervention for AMI were included. Methodological quality was assessed using the Cochrane evaluation manual 5.3.3 criteria. A meta-analysis was performed, and forest plots were drawn."],"journal":["Frontiers in pharmacology"],"pubmed_title":["Comparison of the Efficacy of Danhong Injections at Different Time-points During the Perioperative Period of Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials."],"pmcid":["PMC8117241"],"funding_grant_id":["2017YFC1700402","5141900102"],"pubmed_authors":["Chen Q","Xiao Z","Zhang JH","Zhu WF","Sun X","Chen SX","Zhou X","He QY","Nie HY","Shang HC","Chen XF","Yu XY","Yi XQ"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of the Efficacy of Danhong Injections at Different Time-points During the Perioperative Period of Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","description":"<b>Objectives:</b> Danhong injections (DHI) are widely used in the treatment of acute myocardial infarction (AMI). As there are no guidelines for the timing of DHI in the peri-percutaneous coronary intervention (PCI) period for AMI, we investigated the effects of DHI timing. <b>Methods:</b> We reviewed reports published before September 30, 2020 in PubMed, embase, the Cochrane Central Register of Controlled Trials, the Chinese BioMedical database, Chinese VIP database, Wanfang database, and Chinese National Knowledge Infrastructure database. Only randomized controlled trials of DHI with percutaneous coronary intervention for AMI were included. Methodological quality was assessed using the Cochrane evaluation manual 5.3.3 criteria. A meta-analysis was performed, and forest plots were drawn.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-04T12:33:47.993Z","creation":"2025-04-04T12:33:47.993Z"},"accession":"S-EPMC8117241","cross_references":{"pubmed":["33995051"],"doi":["10.3389/fphar.2021.643446"]}}